Not pretty, but then, you already know that. Rising off the mid-month low is something to be happy about, I guess.
Here's where we stand year to date:
I've noted previously the correlation between the declines in Gilead Sciences (GILD - Get Report) and the broader biotech sector. April broke that trend, which is an encouraging sign that investors are perhaps starting to differentiate between quality stocks and over-valued garbage.
Must Read: Endocyte Falls on Ovarian Cancer Drug Blowup
The April performance of big-cap biotech stocks:
05/19/15 - 04:42 PM EDT
05/19/15 - 12:48 PM EDT
05/18/15 - 08:06 AM EDT
05/05/15 - 02:43 PM EDT
05/05/15 - 10:40 AM EDT
09/04/15 - 12:28 PM EDT
09/04/15 - 12:18 PM EDT
09/04/15 - 08:30 AM EDT
09/03/15 - 08:39 AM EDT
09/02/15 - 19:12 PM EDT
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.